Findx
EnglishEnglish
Dansk Dansk

Genenta Science S.p.A. stock analysis SAEN.US

Genenta Science S.p.A. is undergoing a strategic transformation from a clinical-stage biotech company into a strategic industrial consolidator now branded as Saentra Forge. Its primary business is acquiring and developing privately held Italian and European companies that operate in sectors regulated under national security and industrial sovereignty laws - namely defense, aerospace, cybersecurity, life sciences, biosecurity, and critical infrastructure. This acquisition model is intended to establish a portfolio of sovereign-aligned firms under one industrial group.

Historically the company developed gene therapy and cell-based immunotherapy products using hematopoietic stem cells to deliver immunomodulatory payloads to solid tumors. Its lead product candidate, Temferon, is in clinical trials for glioblastoma multiforme and newly initiated trials in metastatic renal cell carcinoma. The original biotech platform remains part of its operations and is being evaluated for partnerships and broader solid tumor indications, but it is no longer the sole or dominant business focus.

Genenta is headquartered in Milan, Italy, and until mid-2026 operated a U.S. subsidiary which it has decided to close in order to streamline operations and focus on European markets. It will deploy hands-on governance, long-term capital, and industrial integration to build out its acquired businesses. Regulatory compliance, especially under Italy's Golden Power framework, plays a central role in its business strategy.

Industrials · Conglomerates · Conglomerates · Italy
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: Not yet
A short-term bounce, not yet a trend change. Price is above SMA 20, but the moving averages are still falling, so being above them reflects a bounce inside a downtrend rather than a reversal. Wait for the averages to flatten and turn up before entering.
Trend
Trend: Hold
The medium-term trend is intact. Price remains above SMA 20, and none of the profit-protection rules have triggered. Keep holding and let the trend work.
‹
›

Click to see warnings

Neg. values

Log in
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: No reliable interim period / FY2025TTM presentEstimates: UnavailableScored as: Standard companyEvidence: IncompleteDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: No reliable interim period
  • TTM period: ; used by: Quality, Strength
  • No future Diluted EPS estimate is available.
  • Target price: Date unknown, Analyst count unknown

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Unavailable; Not enough evidence; TTM used
Business Momentum: Unavailable; Not enough evidence; TTM not used
Strength: Score calculated; Limited confidence; TTM used
  • Business Momentum score unavailable because too little of the model could be assessed. Missing: Latest surprise, Estimate revisions, Profitability, Revenue.
  • Quality score unavailable because the required anchor metric is missing. Missing: Business Development, Free Cash Flows, Gross Profitability, Margin Stability, Return on Capital.
  • Limited confidence for Strength by model design: diluted EPS stood in for normalized EPS.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx
  • FCF margin: approved fallback

Key stock metrics

Blended P/E  :
P/E (last full year) :
N/A
N/A
Blended EPS  :
USD N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
N/A
Market Cap:USD 33.75 M
EUR 30.06 M

Valuation basis

Analyst price target
How this valuation works
Yearly EPS growth  :
( years incl. estimates)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :
Sign in to view

EPS Estimates

:
N/A
:
N/A
:
N/A

About Genenta Science S.p.A.

Description, revenue sources, strengths and weaknesses

DESCRIPTION

Genenta Science S.p.A. is undergoing a strategic transformation from a clinical-stage biotech company into a strategic industrial consolidator now branded as Saentra Forge. Its primary business is acquiring and developing privately held Italian and European companies that operate in sectors regulated under national security and industrial sovereignty laws - namely defense, aerospace, cybersecurity, life sciences, biosecurity, and critical infrastructure. This acquisition model is intended to establish a portfolio of sovereign-aligned firms under one industrial group.

Historically the company developed gene therapy and cell-based immunotherapy products using hematopoietic stem cells to deliver immunomodulatory payloads to solid tumors. Its lead product candidate, Temferon, is in clinical trials for glioblastoma multiforme and newly initiated trials in metastatic renal cell carcinoma. The original biotech platform remains part of its operations and is being evaluated for partnerships and broader solid tumor indications, but it is no longer the sole or dominant business focus.

Genenta is headquartered in Milan, Italy, and until mid-2026 operated a U.S. subsidiary which it has decided to close in order to streamline operations and focus on European markets. It will deploy hands-on governance, long-term capital, and industrial integration to build out its acquired businesses. Regulatory compliance, especially under Italy's Golden Power framework, plays a central role in its business strategy.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.